Compare Inovio Pharmaceuticals Inc (INO) vs Advanced Drainage Systems Inc (WMS) Price & Performance

INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.

Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.

WMS trades at $142.93, down 3.13% today, with a neutral technical signal and mixed analyst sentiment. The company shows strong profitability with a 13.98% net income margin and 24.02% ROE, though revenue remained flat at $2.90B in 2025. Recent earnings beats and a dividend increase signal management confidence, while cash flow turned negative due to increased investing activities.

The outlook is cautiously optimistic with a consensus price target of $184.43 offering 29% upside. Risks include volatile cash flows and competitive pressures, but consistent earnings outperformance and solid balance sheet strength support a favorable risk-reward profile for long-term investors.